ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$284.47
−0.33%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$284.23
From 52W high−0.33%
Volume1.78M
Market cap$502.69B
P/E (TTM)80.1x
P/S (TTM)7.8x
Div yield2.43%
Key dataOct 19, 2026
Open
$284.23
From 52W high
−0.33%
Volume
1.78M
Market cap
$502.69B
ValuationView details →
P/E (Fwd)
18.2x
EV/EBITDA
26.8x
P/E (TTM)
80.1x
RSI (14)
68.2
MomentumView details →
1D Return
−0.33%
YTD Return
+24.22%
SummaryUpdated Jun 1, 2026
AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company that was spun off from Abbott Laboratories in 2013. The company emerged as an independent entity to focus exclusively on research-based pharmaceuticals, inheriting Abbott's established drug portfolio including the blockbuster immunology drug Humira. Since its inception, AbbVie has evolved from a company heavily dependent on a single product to a diversified pharmaceutical enterprise with a robust pipeline across multiple therapeutic areas. Today, AbbVie operates as one of the world's largest biopharmaceutical companies, with operations spanning immunology, oncology, neuroscience, and aesthetics.
Similar companies
Latest newsMore news →
AbbVie Inc. reported that ABBV-466 achieved higher endoscopic remission rates at Week 12 than anti-IL-23 p19 or anti-α4β7 monotherapy in a Phase 2a Crohn’s disease study, with the treatment difference increasing at Week 24.11h agoAbbVie Inc. announced that new and updated data from seven oncology assets will be presented at the 2026 ESMO Congress in Madrid from October 23 to 27.21h ago